A United Kingdom supplier, with 4 awarded contracts, totalling £769.2m, most recently 4 months ago.
This procurement opportunity involves the establishment of a Dynamic Purchasing System (DPS) for the supply of pharmaceutical products primarily for the Pharmacy of the Faculty Hospital in Olomouc. The aim is to have a wide range of suppliers who will be invited to submit bids for individual public
This public procurement contract involves the supply of medicinal products as specified in the attached documents. The contract is divided into five parts according to the specifications provided in the documentation. Suppliers are invited to submit their offers based on the detailed requirements ou
This public procurement contract involves the supply of goods as specified in Appendix 1 of the invitation (Goods Specification). The contract is divided into parts according to Section 101, paragraph 1 of the Public Procurement Act.
This public procurement contract involves the supply of goods as specified in Appendix 1 of the invitation (Goods Specification). The contract is divided into parts according to Section 101, paragraph 1 of the Public Procurement Act.
This public procurement contract involves the ongoing supply of a medicinal product containing the active ingredient risdiplam (ATC M09AX10). The required formulation is 0.75MG/ML in powder for solution, with a unit measure of 1+AD+5XSTŘ, totaling a quantity of 2,400 units. The contract is valued at
This public procurement contract involves the ongoing supply of pharmaceuticals containing the active ingredients Oseltamivir (J05AH02) and Mycophenolic Acid (L04AA06), including Cellcept, for a duration of 4 years. The total value of the contract is approximately €9,788,990.52. The contract is issu
This public procurement contract involves the ongoing supply of pharmaceuticals containing the active ingredients L04AC07 Tocilizumab (Roactemra) and L04AG08 Okrelizumab for a duration of 4 years. The contracting authority requires only those pharmaceuticals for which the State Institute for Drug Co
